CD8A and neoplasm: By combining CT images and RNA-sequencing genomic data from tumor biopsies of patients with advanced solid tumors (MOSCATO trial) [191], Sun et al. developed a radiomic signature that could discriminate between high (>median) and low (<median) density of CD8+ TILs (AUC: 0.74, p < 0.0001) [187] and validated the findings in three independent advanced solid tumor cohorts: TCGA validation set [192], tumor immune phenotype validation set [193] and immunotherapy-treated validation set [194].